

DAFTAR PUSTAKA

- Adachi, T., Hinoi, T., Hattori, M., Egi, H., Shimomura, M. 2014. The modified Glasgow prognostic score for early mortality in patients with synchronous peritoneal carcinomatosis from colorectal cancer. *Springer Japen*. doi 10.1007/s00595.014.1080.4.
- Albano, J.D., Ward, E., Jemal, A., Anderson, R., Cokkinides, V.E. 2007. Cancer Mortality in the United States by Education Level and Race. *Journal of the National Cancer Institute*, Vol 99 : 1384-1394.
- Alteri, R., Bandi, P., Brooks, D., Cokkinides, V., Doroshenk, M., Gansler, T. 2011. Colorectal Cancer Facts and Figures : 2011-2013. *American Cancer Society*. Available from: <http://www.cancer.org/acs/groups/content/>.
- Boardman, L.A., Morlan, B.W., Rabe, K.G., Petersen, G.M., Lindor, N.M., Ningon, S.K., Goldberg, J., Gallinger, S. 2007. Colorectal Cancer Risks in Relatives of Young-onset Cases: Is Risk the same across all First-degree Relatives?. *Clin Gastroenterol Hepatol*; 5(10):1195–1198.
- Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J.P., Gilberg, F., Cunningham, D. 2011. Efficacy of Capecitabine Versus 5-Fluorouracil in Colorectal and Gastric Cancers: a Meta-analysis of Individual Data from 6171 Patients. *Annals of Oncology*; 22: 2604–2609.
- Cappell, M. S. 2005. The Pathophysiology, Clinical Presentation and Diagnosis of Colon Cancer and Adenomatous Polyps. *The Medical Clinics of North America*, 89: 1-42.
- Choi, K.W., Hong S.W., Chang, Y.G., Lee, W.Y., Paik, I.W., Lee, H. 2014. Inflammation-based Score (Glasgow Prognostic Score) as an Independent Prognostic Factor in Colorectal Patients. *Annals of Surgical Treatment and Research Journal* 309-313.
- Connolly, G.C., Khorana, A.A., Kuderer, N.M., Culakova, E., Francis, C.W., Lyman, G.H. 2010. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. *Thromb Res*, 126(2): 113–118.
- Dahlan, M.S. 2010. Besar Sampel dan Cara Pengambilan Sampel Penelitian. *Salemba Medika* : Jakarta.
- de Gramont, A., Figer, A., Seymour, M. 2000. Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. *J Clin Oncol*; 18: 2938–2947.
- de Jong, A.E., Morreau, H., Nagengast, F.M. 2005. Prevalence of Adenomas Among Young Individuals at Average Risk for Colorectal Cancer. *Am J Gastroenterol*, 100 (1):139–143.
- Divitiis, C.D., Nasti, G., Montano, M., Fisichella, R., Iaffaioli, R.V., Berretta, M. 2014. Prognostic and Predictive Response Factors in Colorectal Cancer Patients: Between Hope and Reality. *World J Gastroenterol* November 7; 20(41): 15049-15059.

- Dubois, R., Wang, D. 2010. The Role of COX-2 in Intestinal Inflammation and Colorectal Cancer. *Oncogene* 29, 781-788.
- Edwards, M., Chadda, S., Zhao, Z., Barber, B., Sykes, D. 2011. A Systematic Review of Treatment Guidelines for Metastatic Colorectal Cancer. *The Association of Coloproctology of Great Britain and Ireland*, 14 : e31-e47.
- Falcone, A. Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Cecilia, B. 2007. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared with Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. *J Clin Oncol*, 25: 1670–1676.
- Geenen, R.W., Hussain, S.M., Cademartini, F., Poley, J.W., Siersema, P.D., Krestin, G.P. 2004. CT and MR Colonography: Scanning Techniques, Postprocessing and Emphasis on Polyp Detection. *RadioGraphics J*, vol.24, No.1.
- Giessen, C., Graeven, U., Laubender, R.P., Modest, D.P., Schulz, C., Porschen, R., Schmiege, W., Reinacher-Schick, A., Hegewisch-Becker, S., Stintzing, S., Heinemann V. 2013. Prognostic Factors for 60-Day Mortality in First-Line Treatment of Metastatic Colorectal Cancer (mCRC): Individual Patient Analysis of Four Randomised, Controlled Trials by The AIO Colorectal Cancer Study Group. *Annals of Oncology* 24: 3051–3055.
- Hanahan D., Weinberg R. 2000. The Hallmarks of Cancer. *Cell* vol.100, 57-70.
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. 2004. Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. *N Engl J Med*, 350: 2335–42.
- Kersten, C., Louhimo, J., Algras, A., Lahdesmaki, A., Cvancerova, M., Stenstedt, K. 2013. Increased C-Reactive Protein Implies a Poorer Stage-specific Prognosis in Colon Cancer. *Actaoncologica*, 52 : 1691-1698.
- Köhne, C.H., Cunningham, D., Di Costanzo, F., Glimelius, B., Blijham, G., Aranda, E. 2002. Clinical Determinants of Survival in Patients with 5-Fluorouracil-based Treatment for Metastatic Colorectal Cancer: Results of a Multivariate Analysis of 3825 Patients. *Ann Oncol*; 13: 308–317.
- Kroenke, C.H., Neugebauer, R., Meyerhardt, J., Prado, C.M., Weltzien, E., Kwan, M.L. 2016. Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams. *JAMA Oncol*. 2(9):1137-1145.
- Lewis, A., Ituarte, P.H., Melstrom, K. 2017. Causes of Death in Long-term Survivors of Colorectal Cancer. *Society of Surgical Oncology Annual Cancer Symposium*. Abstract 53. Presented March 17, 2017.
- Mazhar, D., Ngan S. 2006. C-Reactive Protein and Colorectal Cancer. *Q J Med*, 99: 555-559.

- McMillan, D.C. 2013. The Systemic Inflammation-based Glasgow Prognostic Score : a Decade of Experience in Patient with Cancer. *Cancer Treat rev*, 39 : 534-540.
- Nazha, B., Moussaly, E., Zaarour, M., Weerasinghe, C., Azab, B. 2015. Hypoalbuminemia in Colorectal Cancer Prognosis : Nutritional Marker or Inflammatory Surrogate?. *World J Gastrointest Surg*, 27; 7(12) 370-377.
- Nozoe, T., Matono, R., Ijichi, H., Ohga, T., Ezaki, T. 2014. Glasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma. *Int Surg*; 99(5) : 512-517.
- Otani, T., Iwasaki, M., Sasazuki, S., Inoue, M, Tsugane, S. 2006. Plasma C-Reactive Protein and Risk of Colorectal Cancer in a Nested Case-Control Study : Japan Public Health Center-based Prospective Study. *Cancer Epidemiol Biomarkers Prev*, 15 (4).
- Pourhoseingholi M.A. 2012. Increased Burden of Colorectal Cancer in Asia. *World Journal of Gastrointestinal Oncology*, 4(4) : 68-70.
- Proctor, M.J., Horgan, P.G., Talwar, D., Fletcher, C.D., Morrison, D.S., McMillan, D.C. 2013. Optimization of The Systemic Inflammation-based Glasgow Prognostic Score. *Willey Online Library*, 2325-2332.
- Sharma, R., Zucknick, M., London, R., Kacevska, M., Liddle C., Clarke S.J. 2008. Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-stage Colorectal Cancer. *Clinical Colorectal Cancer Journal*, Vol 7, No.5, 331-337.
- Siegel, R.L., DeSantis C., Jemal, A. 2014. Colorectal Cancer Statistics. *Cancer Journal for Clinicians*. Vol. 64, No.2, 104-117.
- Sohal, D.P., Kuderer, N.M., Sheperd, F.A., Pabinger, I., Agnelli, G., Liebman, H.A. 2017. Clinical Predictor of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy : Results from a Global Prospective Cohort Study. *JNCI Cancer Spectrum*, Vol.1, 1(1).
- Suzanna, E.S. 2012. Registrasi Kanker Berbasis Rumah Sakit di Rumah sakit Kanker Dharmais 2003-2007. Laporan Kerja Subbagian Registrasi Kanker. *Departemen Kesehatan Republik Indonesia*.
- Tavares, B.M., Candido, E.F. 2008. Systemic Leukocyte Alterations in Cancer and Their Relation to Prognosis. *The Open Cancer Journal*, 2 : 53-58.
- Tebbutt, N.C., Wilson, K., Gebiski, V.J., Cummins, M.M, Zannino, D., van Hazel, G.A., Robinson, B. 2010. Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of The Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. *J Clin Oncol*, 28: 3191–3198.
- Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery, D. 2004. FOLFIRI Followed by FOLFOX6 or The Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. *J Clin Oncol*, 22: 229–237.
- Tsilidis, K.K., Branchini, C., Guallar, E., Helzlsouer, K.J., Erlinger, T.P., Platz, E.A. 2008. C-Reactive Protein and Colorectal Cancer Risk : A

- Systematic Review of Prospective Studies. *Int. J. Cancer*, 123, 1133-1140.
- Van Cutsem, E., Cervantes, A., Nordlinger, B., Arnold, D. 2014. Clinical Practice Guidelines of Metastatic Colorectal Cancer : ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Annals of Oncology*, 25 (3): iii1-iii9.
- Voutsadakis, I.A. 2014. Thrombocytosis as a Prognostic Marker in Gastrointestinal Cancers. *World Journal of Gastrointestinal Oncology*, 15; 6(2) : 34-40.
- Yuan, S., Nie, R., Chen, Y., Qiu, H., Li, X., Chen, X. 2018. Glasgow Prognostic Score is Superior to ECOG as a Prognostic Factor in Patients with Gastric Cancer with Peritoneal Seeding. *Oncology letters*, 15 : 4193-4200.
- Navaratnasamy, P. 2014. Cancer Country Profile of Indonesia. *World Health Organization*.
- Zacharakis, M., Xynos, I.D., Lazaris, A., Smaro, T., Kosmas, C., Dokou, A. 2010. Predictors of Survival in Stage IV Metastatic Colorectal Cancer. *Anticancer Research*; 30: 653-660.
- Zauber, A.G., Winawer, S.J., O'Brien, M.J., Lansdrop-Vogelaar, I., Ballegooijen, Hankey, B.F. 2012. Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. *N Engl J Med*: 336(8); 687-689.